mAB production: Step 11 – Sterile Filling and Finishing: From Bulk Drug Substance to Patient‑Ready Vial

How we sterile‑filter, fill, inspect, label, and package the monoclonal antibody under aseptic conditions.

Welcome back to our deep‑dive series on monoclonal antibody manufacturing. In Step 10, we performed ultrafiltration and diafiltration (UF/DF) to concentrate the monoclonal antibody to its final strength (e.g., 50–100 mg/mL) and exchange the buffer into the stable, injectable formulation. The resulting Bulk Drug Substance (BDS) is sterile, pure, and potent – but it is still a bulk liquid in a large bag or tank.

The final journey transforms this bulk into finished drug product – the sterile vials or pre‑filled syringes that reach the patient. Step 11 – Sterile Filling and Finishing encompasses:

• Sterile filtration (final 0.22 µm filtration)

• Filling into primary containers (vials, syringes, cartridges)

• Lyophilization (freeze‑drying) for products that require it

• Capping and crimping

• Inspection (visual and automated)

• Labeling and secondary packaging

• Cold chain storage and distribution

For a liquid mAb like Humira (adalimumab), lyophilization is not required – it is filled as a sterile liquid. However, many biologics are lyophilized for stability. We will cover both approaches.

Let’s walk through each substep, including equipment, critical parameters, and regulatory expectations.

Overview: Aseptic Processing vs. Terminal Sterilization

• Terminal sterilization (e.g., autoclaving) is not possible for most mAbs because heat denatures the protein.

• Therefore, we use aseptic processing: all components (drug substance, containers, closures) are sterilized separately and assembled in a sterile environment (Grade A/ISO 5).

This is one of the most highly regulated areas in pharmaceutical manufacturing because any failure can introduce microorganisms directly into the product.

Step 11.1: Preparation of Bulk Drug Substance

Objective: Thaw (if frozen) and pool the BDS, then perform final sterile filtration.

Process:

1. Receive BDS from UF/DF in sterile, single‑use bags (e.g., 5–50 L bags) or stainless steel vessels. BDS is stored at 2–8°C (or −20°C for long‑term).

2. Thaw (if frozen) in a controlled environment (2–8°C or ambient with mixing). Avoid temperature gradients that could cause aggregation.

3. Pool multiple BDS bags into a sterile holding vessel (the “formulation vessel”) if needed for a large filling batch.

4. Final sterile filtration: Pass the BDS through a 0.22 µm sterilizing‑grade filter (often two filters in series for redundancy). This removes any potential bioburden that may have been introduced after UF/DF.

   • Filter type: Polyethersulfone (PES) or polyvinylidene fluoride (PVDF), low protein binding.

   • Integrity test: Before and after use (bubble point or diffusion test).

5. Hold the sterile filtered BDS in a sterile, jacketed vessel at 2–8°C (or ambient temperature if filling within hours).

Critical parameters:

• Filter integrity (pre‑use and post‑use)

• Bioburden before filtration (must be low, typically <1 CFU/10 mL)

• Filter compatibility with excipients (e.g., polysorbate can cause foaming)

Equipment:

• Sterile filter housing (single‑use or stainless steel)

• Peristaltic pump for transfer

• Integrity tester (e.g., Millipore Integritest, Sartorius Sartocheck)

Step 11.2: Preparation of Primary Containers and Closures

Primary containers hold the drug product directly. For mAbs:

• Glass vials (Type I borosilicate glass) with rubber stoppers and aluminum crimp caps

• Pre‑filled syringes (glass or plastic) with needle shields and plungers

• Cartridges (for auto‑injectors)

Process:

1. Washing (for vials and syringes): Ultrasonic washing with WFI, followed by depyrogenation (dry heat, 250–350°C) to destroy endotoxins.

2. Sterilization (for stoppers, plungers, caps): Autoclaving (121°C, 30 min) or gamma irradiation.

3. Transfer to the filling line under sterile conditions (e.g., via sterile transfer ports or isolators).

Critical parameters:

• Particle load after washing (tested by light obscuration)

• Endotoxin reduction (≥3 log for depyrogenation)

• Sterility assurance level (SAL) of 10⁻⁶

Equipment:

• Vial washing machine (e.g., Bausch+Ströbel, IMA)

• Depyrogenation tunnel (hot air, e.g., Bosch, Optima)

• Autoclave (for stoppers)

Step 11.3: Filling – The Core Operation

Objective: Accurately fill each container with the target volume of sterile drug product.

Filling technologies:

Process:

1. Set up the filling line in a sterile environment (Grade A / ISO 5) within a Grade B / ISO 7 background.

2. Prime the filling needles with drug product until consistent volume is achieved.

3. Fill containers: Vials are indexed under filling needles; syringes are filled through the back or nozzle.

4. Target fill volume (e.g., 1 mL for a 40 mg/0.8 mL Humira prefilled syringe). Tolerance typically ±1–2%.

In‑process controls:

• Weight check: Every 15–30 minutes, weigh filled containers (tare + net) to verify volume. Use density to convert weight to volume.

• Visual inspection for defects: Cracked containers, missing stoppers, visible particles.

• Fill volume trend chart: Immediate action if drift detected.

Equipment:

• Filling machine (e.g., Bausch+Ströbel, IMA, Optima, Groninger)

• In‑line checkweigher (e.g., Mettler Toledo, Sartorius)

• Isolator or RABS (Restricted Access Barrier System) for sterility

Step 11.4: Stoppering and Capping (for Vials)

Objective: Seal the vial with a rubber stopper and secure with an aluminum crimp cap.

Process:

1. Stoppering: Immediately after filling, a sterilized rubber stopper is partially inserted (or fully seated under vacuum/nitrogen).

   • Oxygen reduction: Many mAbs are sensitive to oxidation. The headspace may be flushed with nitrogen before full stoppering.

2. Capping: Aluminum crimp caps are placed over the stopper and pressed (crimped) to form a tight seal.

3. Check seal integrity: In‑line vision system or manual inspection.

For pre‑filled syringes: After filling, the plunger is inserted (often with a vented stopper), then the needle shield is added. The process is similar but syringe‑specific.

Equipment:

• Stoppering station (within the filling machine)

• Capping machine (e.g., Bausch+Ströbel, IMA)

• Nitrogen flushing system (if required)

Step 11.5: Lyophilization (Freeze‑Drying) – For Products That Require It

Many biologics are unstable in liquid form and require lyophilization (freeze‑drying). For Humira, this is not needed, but for other mAbs (e.g., some biosimilars or fusion proteins), it is common.

Process overview:

1. Freezing: Vials are loaded onto shelves in a lyophilizer. Temperature is lowered to −40 to −50°C, freezing the water in the formulation.

2. Primary drying (sublimation): Pressure is reduced (to <0.1 mbar), and shelf temperature is raised slightly (e.g., to −20°C). Ice sublimates directly to vapor, leaving a porous cake.

3. Secondary drying (desorption): Temperature is raised further (e.g., to 20–40°C) to remove bound water, resulting in a dry, stable cake (residual moisture typically 0.5–2%).

4. Stoppering under vacuum or nitrogen: The vials are stoppered inside the lyophilizer to maintain the inert atmosphere.

Critical parameters:

• Ramp rates (freezing and heating)

• Shelf temperature and chamber pressure during primary drying

• Residual moisture (tested by Karl Fischer)

Equipment:

• Production‑scale lyophilizer (e.g., IMA Edwards, GEA Lyophil, SP Scientific) with shelves for 10,000–50,000 vials

• Automated loading/unloading systems (to maintain sterility)

Step 11.6: Inspection – Removing Defective Units

Every filled container must be inspected for defects. Two methods are used in combination:

1. Automated visual inspection (AVI): High‑speed cameras and sensors detect:

• Particulates (visible particles – glass, rubber, fibers, protein aggregates)

• Fill level (over/under)

• Container defects (cracks, chips)

• Stopper/crimp defects (misaligned, damaged)

2. Manual visual inspection (backup): Trained inspectors view each vial/syringe against black and white backgrounds under high illumination (2,000–3,000 lux). Used for rejects from AVI or for small batches.

Acceptance criteria (USP <790>, EP 2.9.20): Visible particles must be absent. A statistically validated sampling plan is used.

Reject rate: Typically 1–5% of vials are rejected during inspection (higher for difficult products).

Equipment:

• Automated inspection machine (e.g., Eisai, Sensum, Korber, Bausch+Ströbel)

• Manual inspection booths with controlled lighting

Step 11.7: Labeling and Secondary Packaging

Objective: Apply the product label (including lot number, expiry, barcode) and place containers into cartons or trays.

Process:

1. Labeling: Vials or syringes are labeled with pressure‑sensitive labels. Labels are verified by vision systems (barcode reading, optical character recognition).

2. Leaflet insertion: For cartons, a package insert (patient information leaflet) is added.

3. Cartoning: Vials/syringes are placed into cartons (primary carton). Multiple cartons are packed into shippers (secondary packaging).

4. Serialization: Each carton receives a unique 2D barcode (GS1, DSCSA compliance in the US, FMD in EU) for track‑and‑trace.

5. Aggregation: Shippers are linked to cartons (parent‑child relationship) for supply chain visibility.

Equipment:

• Labeling machine (e.g., Newman, Pago, Accraply)

• Cartoner (e.g., IWK, Marchesini, Bausch+Ströbel)

• Serialization system (e.g., SeaVision, Antares Vision)

• Case packer and palletizer

Step 11.8: Environmental and Sterility Assurance

The entire filling and finishing operation must maintain strict environmental control:

Monitoring:

• Non‑viable particles (continuous or periodic)

• Viable particles (settle plates, active air samplers, contact plates)

• Operator gowning (frequent qualification)

Media fills: At least twice per year, simulate the filling process with sterile growth medium instead of drug product. Incubate all filled containers and demonstrate zero growth (or ≤0.1% contamination with appropriate investigation). This validates the aseptic process.

Step 11.9: Quality Control Testing for Finished Drug Product

Before release, each batch undergoes extensive QC testing:

Stability testing: At least 3 batches are placed on stability (long‑term at 2–8°C, accelerated at 25°C/60% RH, and sometimes 40°C for stress). Stability protocol includes assays at multiple timepoints (e.g., 0, 3, 6, 9, 12, 18, 24 months).

Step 11.10: Storage and Distribution (Cold Chain)

The finished drug product (vials or syringes) is stored at 2–8°C (refrigerated) for liquid mAbs. Freezing is avoided (can cause aggregation).

Cold chain requirements:

• Qualified temperature‑controlled shippers (with data loggers)

• Real‑time temperature monitoring (optional but recommended)

• Stability‑based excursions: A limited temperature excursion (e.g., up to 25°C for 24 hours) may be allowed based on stability data.

For lyophilized products: Room temperature storage may be possible, but many still require refrigeration.

What Can Go Wrong? (Troubleshooting Step 11)

What Comes Next?

With Step 11, the manufacturing process is complete. The finished drug product is packaged, labeled, and ready for release to patients.

In a final wrap‑up post, we will summarize the entire journey – from gene to injection – and discuss critical quality attributes (CQAs), process validation, and the regulatory framework that ties all these steps together.

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:

www.manostaxx.com